Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
three other compounds have been approved in Japan (Ipragliflozin, Tofogliflozin, Luseogliflozin), while others are in development (Ertugliflozin and Sotagliflozin) ( Canagliflozin Canagliflozin [(1 S )-1,5-andro-1-[3-[[5-(4-fluorophenyl)-2-tienil]metil]-4-metilfenil]-d- GLUCITOLO emirate], is a C-glycosyl compound that is used (in the hemihydrate form) for the treatment of T2DM through inhibition of sodium/glucose co-transporter 2 ( It was initially approved by the FDA in 2013 for the management of T2DM and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with T2DM
More details coming soon
Footnotes Minor corrections of references such that in-text references and bibliography match
W., Wong, K
Slowing the advancement of diseases such as osteoarthritis, rheumatoid arthritis, and gout
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes
US$ 21.23
US$ 23.47
US$ 20.45
